Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Larimar Therapeutics, Inc. | d45341dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 22, 2015
Zafgen, Inc.
(Exact name of registrant as specified in its charter)
DELAWARE | 001-36510 | 20-3857570 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
175 Portland Street Boston, MA |
02114 | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code (617) 622-4003
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events
On October 22, 2015, Zafgen, Inc. issued a press release announcing that it has elected to close the randomized portion of its Phase 3 ZAF-311 clinical trial of beloranib in patients with Prader-Willi syndrome and its ZAF-203 Phase 2b clinical trial of beloranib in patients with severe obesity complicated by type 2 diabetes to proceed with analysis of the data from these trials. A copy of the statement is filed herewith as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Exhibits.
(d) Exhibits
Exhibit |
Description | |
99.1 | Press release issued by Zafgen, Inc. on October 22, 2015. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 22, 2015 | ZAFGEN, INC. | |||||
By: | /s/ Thomas E. Hughes | |||||
Thomas E. Hughes. Ph.D. | ||||||
Chief Executive Officer |
3
EXHIBIT INDEX
Exhibit No. |
Description | |
99.1 | Press release issued by Zafgen, Inc. on October 22, 2015. |
4